Satellite Symposia

Make room in your agenda and join these interesting satellite symposia!

Wednesday, 26 October 2022

13:15 – 14:15, Hall 12

Satellite Symposium 1 – Connecting the Dots: immune cells and CNS inflammation
Chair: Celia Oreja-Guevara (Madrid, ES), Gavin Giovannoni (London, UK)

CNS immune cells in MS
Speaker: Joost Smolders (Rotterdam, NL)

Targeting CNS immune pathology early in MS
Speaker: Veronica Popescu (Pelt, BE)

The challenges of long-term B-cell suppression
Speaker: Gavin Giovannoni (London, UK)

Immune reconstitution therapy: reasons to start and continue
Speaker: Celia Oreja-Guevara (Madrid, ES)

supported by

13:15 – 14:15, Elicium 1&2

Satellite Symposium 2 – Evolving the Paradigm of Patient Care in MS and Forging the Path Ahead
Chair: Stephen Hauser (San Francisco, US)

Our progress so far: The changing paradigm in MS treatment
Speaker: Stephen Hauser (San Francisco, US)

Assessing our advances: The evolving measures of MS
Speaker: Frauke Zipp (Mainz, DE)

Paving a path forward: Expanding our knowledge of MS through clinical trials
Speaker: Daniel Ontaneda (Cleveland, US)

supported by

17:30 – 18:30, Hall 12

Satellite Symposium 3 – Precision medicine: targeting complement in the prevention of NMOSD* relapses (*Neuromyelitis Optica Spectrum Disorder)
Chair: Sean J Pittock (Rochester, US)

Clinical experience of a complement-targeting therapeutic approach in AQP4+ NMOSD
Speaker: Sean J Pittock (Rochester, US)

Real-world evidence of targeting complement in patients with AQP4+ NMOSD
Speaker: Jin Nakahara (Tokyo, JP)

The importance of complement in the pathophysiology of neuroimmunological diseases
Speaker: Orhan Aktas (Düsseldorf, DE)

supported by

17:30 – 18:30, Elicium 1&2

Satellite Symposium 4 – Putting your everyday patient first: The here and now in RRMS
Chair: Xavier Montalban (Barcelona, ES), Joep Killestein (Amsterdam, NL)

Let’s talk about acting early
Speaker: Pietro Annovazzi (Gallarte, Italy)

Special needs in your everyday patients
Speaker: Karen Chung (London, US)

SPECIAL LECTURE: Time is brain and personalized medicine remains the key
Speaker: Xavier Montalban (Barcelona, ES)

supported by

Thursday, 27 October 2022

08:45 – 09:45, Hall 12

Satellite Symposium 5 – Zooming in on MS: Exploring treatment consensus and controversy surrounding complex patients
Chair: Eva Kubala Havrdová (Prague, CZ)

What evidence do the guidelines provide?
Speaker: Frauke Zipp (Mainz, DE)

How can we handle complex scenarios in clinical practice?
Speaker: Bart Wijmeersch (Hasselt, BE), Sonia Batista (Coimbra, PT)

What evidence do the guidelines provide?
Speaker: Frauke Zipp (Mainz, DE)

How can we handle complex scenarios in clinical practice?
Speaker: Bart Wijmeersch (Hasselt, BE), Sonia Batista (Coimbra, PT)

supported by

08:45 – 09:45, Elicium 1&2

Satellite Symposium 6 – STEP INTO THE NEW ERA OF NMOSD
Chair: Hans-Peter Hartung (Düsseldorf, DE)

From MS to NMO – past, present and future of NMOSD, diagnosis and care
Speaker: Jérôme de Seze (Strasbourg, FR)

Potential advantages of anti-CD19 over anti-CD20 treatments
Speaker: Brian Weinshenker (Rochester, US)

The clinical relevance of inebilizumab for NMOSD AQP4+ adult patients
Speaker: Orhan Aktas (Düsseldorf, DE)

supported by

13:45 – 14:45, Hall 12

Satellite Symposium 7 – Cognitive Impairment in MS
Chair: Hans-Peter Hartung (Düsseldorf, DE)Cognitive Impairment (CI)

Occurs Early in MS
Speaker: Bruno Brochet (Bordeaux, FR)

Impact of CI on Employment, Driving Ability and ADLs
Speaker: Iris-Katharina Penner (Bern, CH)

Association of CI with Early MRI Alterations and Brain Atrophy
Speaker: Bianca Weinstock-Guttman (Buffalo, US)

Early Intervention with Ozanimod Achieves Brain Preservation and Delays CI
Speaker: Hans-Peter Hartung (Düsseldorf, DE)

supported by

13:45 – 14:45, Elicium 1&2

Satellite Symposium 8 – Strategies in MS Care: Evolving Approaches Across the Lifespan
Chair: Joep Killestein (Amsterdam, NL)

The future of evidence generation for better care in MS
Speaker: Helmut Butzkueven (Melbourne, AU)

Treatment decision making in early life stages
Speaker: Ann Yeh (Toronto, CA)

Re-evaluating treatment decisions in the longer term
Speaker: Enrique Alvarez (Denver, US)

supported by

18:00 – 19:00, Auditorium

Satellite Symposium 9 – Ofatumumab in clinical practice: Expert experience & case-based discussion
Chair: Wallace Brownlee (London, UK), Ann Cabot (Concord, US), Ralf Gold (Bochum, DE)

High-efficacy treatment early: Challenging the status quo
Speaker: all Faculty

Considerations for clinicians treating with ofatumumab: The benefit-risk profile
Speaker: all Faculty

Clinical expereince with ofatumumab: A case-based discussion
Speaker: all Faculty

supported by

18:00 – 19:00, Elicium 1&2

Satellite Symposium 10 – Smouldering Disease: Hiding in Plain Sight
Chair: Ann Bass (San Antonio, US)

Following the clues: Underlying Pathological Neuroinflammation
Speaker: Gavin Giovannoni (London, UK)

The Unexplored Alley: Intrinsic CNS Inflammatory Pathways
Speaker: Heinz Wiendl (Muenster, DE)

Exploring Within: CNS Bioactivity
Speaker: Benjamin Greenberg (Dallas, US)

supported by

Friday, 28 October 2022

14:15 – 15:15, Hall 12

Satellite Symposium 11 – New tools for new challenges in multiple sclerosis
Chair: Stephen Krieger (New York, US)

Re-thinking MS progression: is it a disease continuum?
Speaker: Stephen Krieger (New York, US)

Imaging of ongoing central inflammation: Slowly expanding lesions and paramagnetic rim lesions
Speaker: Colm Elliot (Montreal, CA)

Challenges in detecting progression early in MS and emerging role of patient-reported outcomes
Speaker: Marcus D’Souza (Basel, CH)

Can we target ongoing central inflammation? Lessons from the BTK pathway
Speaker: Jacqueline Nicholas (Columbus, US)

supported by

14:15 – 15:15, Elicium 1&2

Satellite Symposium 12 – In with the new: Navigating the modern world of NMOSD management
Chair: Cheryl Hemingway (London, UK)

Charting a course: A case-led approach to choosing the right treatment
Speaker: Cheryl Hemingway (London, UK), Marius Ringelstein (Düsseldorf, DE), Benjamin Greenberg (Dallas, USA), Jin Nakahara (Tokyo, JP)

What lies beneath: Mechanisms and therapeutic options in NMOSD
Speaker: Marius Ringelstein (Düsseldorf, DE)

Current position: Long-term clinical trial data
Speaker: Benjamin Greenberg (Dallas, US)

Broadening horizons: Clinical experience with the approved therapies
Speaker: Jin Nakahara (Tokyo, JP)

Turning the tide: Real-world impact of the approved therapies
Speaker: Cheryl Hemingway (London, UK), Marius Ringelstein (Düsseldorf, DE), Benjamin Greenberg (Dallas, USA), Jin Nakahara (Tokyo, JP)

supported by